West Pharma Posts Strong Q3 Sales, Net Income Up 2.9%

TL;DR

**WST is a solid buy, showing consistent sales growth and strong cash generation despite a slight nine-month net income dip.**

AI Summary

WEST PHARMACEUTICAL SERVICES INC reported a robust financial performance for the three and nine months ended September 30, 2025. For the three-month period, net sales increased by 7.7% to $804.6 million from $746.9 million in the prior year, while net income rose by 2.9% to $140.0 million from $136.0 million. Diluted EPS also saw an increase, reaching $1.92 compared to $1.85 in the same quarter last year. Over the nine-month period, net sales grew by 5.8% to $2,269.1 million from $2,144.4 million, though net income slightly decreased by 0.3% to $361.6 million from $362.6 million. Diluted EPS for the nine months increased to $4.97 from $4.91. The company's cash and cash equivalents significantly increased to $628.5 million at September 30, 2025, up from $484.6 million at December 31, 2024. Strategic outlook includes continued investment in property, plant, and equipment, with net PP&E increasing to $1,740.6 million from $1,581.6 million, and a focus on High-Value Product Components, which now represent 48% of net sales for the quarter. Risks include foreign currency translation adjustments, which resulted in a $12.0 million loss for the quarter, impacting comprehensive income.

Why It Matters

This filing indicates West Pharmaceutical Services is maintaining growth, particularly in its High-Value Product Components segment, which is crucial for investors seeking exposure to the high-growth biologics and pharma markets. The increase in cash and cash equivalents provides financial flexibility for future investments or shareholder returns, despite a slight dip in nine-month net income. For employees, continued revenue growth suggests stability and potential for expansion. Customers benefit from West's sustained investment in property, plant, and equipment, implying enhanced production capabilities and product innovation. In a competitive landscape, West's consistent performance and focus on high-value products position it favorably against peers in the pharmaceutical packaging and delivery systems sector.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant negative foreign currency translation adjustments of $(12.0) million for the three months ended September 30, 2025, compared to a gain of $74.7 million in the prior year, which significantly impacted comprehensive income. Additionally, while net income for the quarter increased, the nine-month net income slightly decreased from $362.6 million in 2024 to $361.6 million in 2025, indicating some pressure on profitability over a longer horizon.

Analyst Insight

Investors should consider WST for its consistent revenue growth and strong cash position, especially given its focus on high-value product components. Monitor foreign currency fluctuations and their impact on comprehensive income, but the underlying business appears robust. The completion of share repurchase programs suggests a potential shift in capital allocation strategies, which warrants attention.

Financial Highlights

debt To Equity

N/A

revenue

$804.6M

operating Margin

20.8%

total Assets

N/A

total Debt

N/A

net Income

$140.0M

eps

$1.92

gross Margin

36.6%

cash Position

$628.5M

revenue Growth

+7.7%

Revenue Breakdown

Key Numbers

• $804.6M — Net Sales (Q3 2025) (Increased 7.7% from $746.9M in Q3 2024)
• $140.0M — Net Income (Q3 2025) (Increased 2.9% from $136.0M in Q3 2024)
• $1.92 — Diluted EPS (Q3 2025) (Increased from $1.85 in Q3 2024)
• $2,269.1M — Net Sales (9 Months 2025) (Increased 5.8% from $2,144.4M in 9 Months 2024)
• $361.6M — Net Income (9 Months 2025) (Slightly decreased from $362.6M in 9 Months 2024)
• $628.5M — Cash and Cash Equivalents (Increased from $484.6M at Dec 31, 2024)
• 48% — HVP Components Net Sales (Percentage of net sales for Q3 2025, up from 45% in Q3 2024)
• $(12.0)M — Foreign Currency Translation Adjustments (Loss for Q3 2025, compared to $74.7M gain in Q3 2024)
• $134.0M — Shares Purchased under Repurchase Programs (Total cost for 9 months ended Sept 30, 2025)
• $1,740.6M — Property, Plant and Equipment, net (Increased from $1,581.6M at Dec 31, 2024)

Key Players & Entities

• WEST PHARMACEUTICAL SERVICES INC (company) — registrant
• Daikyo Seiko, Ltd. (company) — affiliate and distributorship agreement partner
• FASB (regulator) — Financial Accounting Standards Board
• SEC (regulator) — U.S. Securities and Exchange Commission
• Board of Directors (person) — approved share repurchase programs
• $804.6 million (dollar_amount) — net sales for Q3 2025
• $140.0 million (dollar_amount) — net income for Q3 2025
• $628.5 million (dollar_amount) — cash and cash equivalents at September 30, 2025
• $12.0 million (dollar_amount) — foreign currency translation loss for Q3 2025
• 71,943,412 (dollar_amount) — shares of common stock outstanding as of October 20, 2025

FAQ

Risk Factors

• Foreign Currency Fluctuations [medium — financial]: The company experienced a $12.0 million loss from foreign currency translation adjustments in Q3 2025, which negatively impacted comprehensive income. This contrasts with a $74.7 million gain in the same quarter of the prior year, highlighting significant volatility.

Industry Context

West Pharmaceutical Services operates in the pharmaceutical packaging and delivery systems industry, a critical sector supporting global healthcare. The industry is characterized by stringent regulatory requirements, a focus on innovation for drug delivery, and increasing demand driven by an aging global population and advancements in biopharmaceuticals. Competition often centers on product quality, reliability, and technological capabilities in containment and delivery solutions.

Regulatory Implications

As a key supplier to the pharmaceutical industry, West Pharmaceutical Services is subject to rigorous quality and manufacturing standards mandated by regulatory bodies like the FDA. Compliance with these regulations is paramount to maintaining market access and customer trust. Any deviations could lead to significant penalties, product recalls, and reputational damage.

What Investors Should Do

1. Monitor the growth and profitability of High-Value Product Components.
2. Assess the impact of foreign currency fluctuations on overall profitability.
3. Evaluate the company's investment in Property, Plant, and Equipment (PP&E).

Glossary

High-Value Product Components

These are specialized components within West Pharmaceutical Services' product offerings that are likely to command higher prices or margins due to their complexity, technology, or application. (The increasing percentage of net sales from these components (48% in Q3 2025) suggests a successful strategy to shift towards more profitable product lines.)

Foreign currency translation adjustments

These are gains or losses that result from converting the financial statements of foreign subsidiaries from their local currency to the reporting currency of the parent company. (A significant loss of $12.0 million in Q3 2025 impacted the company's comprehensive income, indicating exposure to currency exchange rate fluctuations.)

Comprehensive income

This includes all changes in equity during a period from non-owner sources, such as net income plus other comprehensive income (or minus other comprehensive loss). (The foreign currency translation loss of $12.0 million directly reduced West Pharmaceutical Services' comprehensive income for the quarter.)

Year-Over-Year Comparison

West Pharmaceutical Services demonstrated strong top-line growth in Q3 2025, with net sales increasing by 7.7% year-over-year to $804.6 million, driven by a strategic shift towards High-Value Product Components. While net income saw a modest 2.9% increase to $140.0 million, the nine-month net income experienced a slight decrease of 0.3%. A notable change is the significant swing in foreign currency translation adjustments, from a $74.7 million gain in Q3 2024 to a $12.0 million loss in Q3 2025, impacting comprehensive income. The company also significantly increased its cash position to $628.5 million and continued to invest in its asset base, with net PP&E growing.

Key Financial Figures

• $0.25 — ich registered Common Stock, par value $0.25 per share WST New York Stock Exchange

Filing Documents

• wst-20250930.htm (10-Q) — 1630KB
• ex311q32025.htm (EX-31.1) — 8KB
• ex312q32025.htm (EX-31.2) — 8KB
• ex321q32025.htm (EX-32.1) — 3KB
• ex322q32025.htm (EX-32.2) — 3KB
• wst-20250930_g1.jpg (GRAPHIC) — 17KB
• 0000105770-25-000093.txt ( ) — 9846KB
• wst-20250930.xsd (EX-101.SCH) — 43KB
• wst-20250930_cal.xml (EX-101.CAL) — 88KB
• wst-20250930_def.xml (EX-101.DEF) — 212KB
• wst-20250930_lab.xml (EX-101.LAB) — 652KB
• wst-20250930_pre.xml (EX-101.PRE) — 453KB
• wst-20250930_htm.xml (XML) — 2136KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) Condensed Consolidated Statements of Income for the Three and Nine Months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Comprehensive Income for the Three and N i ne Months ended September 30, 2025 and 2024 4 Condensed Consolidated Balance Sheets at September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Cash Flows for the N ine Months ended Sep tember 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 27

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 39

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 39

OTHER INFORMATION

PART II. OTHER INFORMATION

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 40

RISK FACTORS

ITEM 1A. RISK FACTORS 40

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 40

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 40

EXHIBITS

ITEM 6. EXHIBITS 41 SIGNATURE 42 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) West Pharmaceutical Services, Inc. and Subsidiaries (in millions, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net sales $ 804.6 $ 746.9 $ 2,269.1 $ 2,144.4 Cost of goods and services sold 510.3 482.2 1,469.0 1,419.5 Gross profit 294.3 264.7 800.1 724.9 Research and development 17.1 15.5 52.5 50.6 Selling, general and administrative expenses 102.7 83.5 286.6 253.2 Other expense (income) (Note 14) 6.9 4.4 32.7 10.8 Operating profit 167.6 161.3 428.3 410.3 Interest expense, net 0.2 0.7 0.7 3.8 Interest income ( 4.7 ) ( 4.6 ) ( 12.4 ) ( 14.8 ) Other nonoperating expense (income) 0.2 0.7 0.6 0.7 Income before income taxes and equity in net income of affiliated companies 171.9 164.5 439.4 420.6 Income tax expense 34.0 32.4 88.3 70.7 Equity in net income of affiliated companies ( 2.1 ) ( 3.9 ) ( 10.5 ) ( 12.7 ) Net income $ 140.0 $ 136.0 $ 361.6 $ 362.6 Net income per share: Basic $ 1.94 $ 1.87 $ 5.00 $ 4.96 Diluted $ 1.92 $ 1.85 $ 4.97 $ 4.91 Weighted average shares outstanding: Basic 72.2 72.8 72.3 73.1 Diluted 72.6 73.4 72.7 73.8 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) West Pharmaceutical Services, Inc. and Subsidiaries (in millions) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net income $ 140.0 $ 136.0 $ 361.6 $ 362.6 Other comprehensive (loss) income, net of tax: Foreign currency translation adjustments, net of tax of $ 0.7 and $( 2.5 ), $( 1.4 ) and $( 0.8 ), respectively ( 12.0 ) 74.7 153.3 6.7 Defined benefit pension and other postretirement plan adjustments, net of tax of $ 0.0 and $( 0.2 ), $( 0.3 ) and $( 0.3 ), respectively 0.1 ( 0.8 ) ( 1.0 ) ( 1.2 ) Net (loss) gain on equity affiliate accumulated other comp

View Full Filing

View this 10-Q filing on SEC EDGAR